← All trials
NCT05512403
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 30, 2023
- Primary completion
- Jan 30, 2025
- Completion date
- Oct 30, 2025
- First posted
- Aug 23, 2022
- Last posted
- Aug 24, 2022
- Enrollment
- 88
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of LorraineLead sponsor
- University of Western BrittanyOverall official - principal investigator
- François Rabelais UniversityOverall official - principal investigator
- University of LilleOverall official - principal investigator
- University of LyonOverall official - principal investigator
- University of NantesOverall official - principal investigator
- University of ParisOverall official - principal investigator
- University of NimesOverall official - principal investigator
- Aix-University of MarseilleOverall official - principal investigator
- University of GrenobleOverall official - principal investigator
- University of LorraineOverall official - principal investigator
- University of LorraineOverall official - principal investigator
- University of LorraineReponsible party - principal investigator
- Institut de Cancerologie Strasbourg EuropeOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.